Prelude Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-16,688
| Closed | -$25K | – | 1140 |
|
|
2023
Q1 | $25K | Buy |
+16,688
| New | +$25K | ﹤0.01% | 939 |
|
|
2022
Q4 | – | Sell |
-11,465
| Closed | -$13K | – | 1338 |
|
|
2022
Q3 | $13K | Buy |
+11,465
| New | +$13K | ﹤0.01% | 1233 |
|
|
2021
Q2 | – | Sell |
-17,529
| Closed | -$41K | – | 1509 |
|
|
2021
Q1 | $41K | Buy |
+17,529
| New | +$41K | ﹤0.01% | 1044 |
|
|
2017
Q4 | – | Sell |
-4,115
| Closed | -$10K | – | 1411 |
|
|
2017
Q3 | $10K | Buy |
4,115
+1,257
| +44% | +$3.06K | ﹤0.01% | 1304 |
|
|
2017
Q2 | $8K | Sell |
2,858
-31,089
| -92% | -$87K | ﹤0.01% | 1305 |
|
|
2017
Q1 | $102K | Buy |
33,947
+28,918
| +575% | +$86.9K | 0.01% | 729 |
|
|
2016
Q4 | $16K | Buy |
+5,029
| New | +$16K | ﹤0.01% | 1285 |
|
|
2014
Q3 | – | Sell |
-9,498
| Closed | -$23K | – | 1869 |
|
|
2014
Q2 | $23K | Buy |
9,498
+929
| +11% | +$2.25K | ﹤0.01% | 1533 |
|
|
2014
Q1 | $23K | Buy |
+8,569
| New | +$23K | ﹤0.01% | 1466 |
|